Beckman Coulter Backs Down, Biosite Says ‘Yes’ to Inverness
After a bidding war lasting more than a month, Biosite is on the verge of merging with Inverness Medical Innovations.
This week, Biosite said that it intends to accept a takeover bid by Inverness after its board determined the latest Inverness offer of $92.50 per share is superior to an offer by Beckman Coulter of $90 per share.
Beckman responded by saying it would not raise its bid.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.